Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

Background/Aims Adefovir dipivoxil (10mg once-daily) was added to antiretroviral therapy including lamivudine in 35 HIV/HBV co-infected patients. Methods Parameters evaluated included alanine aminotransferase (ALT), HBV DNA and serological markers, HIV-1 RNA, and CD4+ cell count. Results Twenty-nine patients (83%) completed 144 weeks. Serum HBV DNA declined from a baseline 9.76log10 copies/mL (median) to 4.68, 5.24, and 5.90log10 copies/mL at weeks 48, 96, and 144, respectively ( P P = Conclusions Treatment with adefovir dipivoxil for 144 weeks was well tolerated and resulted in significant and sustained reductions in HBV DNA and ALT in HIV/HBV co-infected patients. Efficacy increased with treatment duration, with no loss of viral suppression.